Clinical Trial Update: Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL) [Phase 2]

View source ↗

Summary

This is a Phase 2 trial evaluating haploidentical natural killer cells with epratuzumab for relapsed acute lymphoblastic leukemia; the study was terminated with…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia

Drugs mentioned

• Epratuzumab (epratuzumab)
• Haploidentical natural killer cells

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Leukemia, Pediatric Cancer | Phase 2 | Status: TERMINATED | Results posted: 2013-08-28